Meet 2022 Young Investigator Award Recipient, Dr. Rosenberg. He is an Assistant Professor in the Department of Medicine at the University of Chicago. His work asks: can circulating tumor DNA guide how doctors should use immunotherapy in head and neck cancer?
Dr. Rosenberg intends to develop a personalized, dynamic, biomarker-driven treatment roadmap for patients with recurrent and/or metastatic head and neck cancer, allowing doctors to strategically combine immunotherapy with chemotherapy to improve treatment efficacy while reducing treatment-related toxicity.
The data Dr. Rosenberg plans to collect will be a first step towards a novel, adaptive, and personalized treatment program of immunotherapy and chemotherapy that will lead to improved survival and lower side effects in patients with recurrent and metastatic head and neck cancer, allowing doctors to implement personalized treatment strategies rather than a “one-size-fits-all” approach.
|